Marvel Biosciences Corp. (TSXV:MRVL)

Marvel Biosciences Cash Flow Statement

Financials in millions CAD. Fiscal year is August - July.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Apr 30, 2026	Jul 31, 2025	Jul 31, 2024	Jul 31, 2023	Jul 31, 2022	Jul 31, 2021
Net Income	-1.39	-2.21	-1.65	-2.29	-2.55	-3.04
Depreciation & Amortization	-	-	-	-	0	0
Stock-Based Compensation	0.04	0.08	0.08	0.08	-	-
Other Adjustments	0.29	0.69	0.21	-	-	1.78
Changes in Accounts Payable	0.21	0.42	0.21	0.67	0.61	-0.08
Changes in Other Operating Activities	0	-0.12	-0.03	0.2	-0.25	-0.04
Operating Cash Flow	-0.78	-1.15	-1.18	-1.33	-2.19	-1.37
Other Investing Activities	-	-	-	-	-	0.38
Investing Cash Flow	-	-	-	-	-	0.38
Long-Term Debt Issued	-	-	0.5	1	-	-
Net Long-Term Debt Issued (Repaid)	-	-	0.5	1	-	-
Issuance of Common Stock	0.85	1.02	0.5	0.27	0.42	3.36
Net Common Stock Issued (Repurchased)	0.85	1.02	0.5	0.27	0.42	3.36
Other Financing Activities	-0.03	-0.09	-0.03	0.03	-0.03	-0.21
Financing Cash Flow	0.82	0.93	0.97	1.3	0.39	3.16
Net Cash Flow	0.18	-0.22	-0.21	-0.04	-1.8	2.17
Free Cash Flow	-0.78	-1.15	-1.18	-1.33	-2.19	-1.37
Free Cash Flow Per Share	-0.01	-0.02	-0.03	-0.03	-0.07	-0.08
Levered Free Cash Flow	-1.18	-1.92	-0.97	-0.41	-2.19	-3.15
Unlevered Free Cash Flow	-1.18	-1.26	-1.09	-1.5	-2.19	-3.28

Data Source: Fiscal.ai Last updated: Jun 18, 2026

Financial data is provided by Fiscal.ai and updates within minutes after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Jul 21, 2026

Data Sources Report a data error